Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CATALYST PHARMACEUTICALS, INC. Director's Dealing 2024

Nov 13, 2024

31542_dirs_2024-11-13_d43372b6-fe94-4d29-a292-9c741289aba0.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2024-11-11

Reporting Person: MCENANY PATRICK J (Director, Chairman of Board of Directors)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-11-11 Common stock, par value $0.001 per share M 230000 $4.01 Acquired 4708169 Direct
2024-11-11 Common stock, par value $0.001 per share S 230000 $23.548 Disposed 4478169 Direct
2024-11-12 Common stock, par value $0.001 per share M 70000 $4.01 Acquired 4548169 Direct
2024-11-12 Common stock, par value $0.001 per share S 70000 $23.421 Disposed 4478169 Direct
2024-11-12 Common stock, par value $0.001 per share M 192000 $3.54 Acquired 4670169 Direct
2024-11-12 Common stock, par value $0.001 per share S 192000 $23.201 Disposed 4478169 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-11-11 Options to purchase common stock $4.01 M 230000 Disposed 2025-01-02 Common Stock (230000) Direct
2024-11-12 Options to purchase common stock $4.01 M 70000 Disposed 2025-01-02 Common Stock (70000) Direct
2024-11-12 Options to purchase common stock $3.54 M 192000 Disposed 2025-05-29 Common Stock (192000) Direct

Footnotes

F1: Shares were sold for personal reasons, including paying federal income taxes and diversifying the Reporting Person's portfolio. Shares were not sold as a result of any disagreement with the Company. Mr. McEnany remains the non-executive chairman of the Company's Board of Directors and the Company's largest individual, non-institutional shareholder.

F2: Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $23.29 to $23.873 per share.

F3: Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $23.30 to $23.50 per share.

F4: Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $23.03 to $23.48 per share.

F5: Options vested in three equal tranches on January 2, 2019, 2020 and 2021.

F6: Options vested in three equal tranches on May 29, 2019, 2020 and 2021.